NZYM B Novozymes A/S Class B

Novonesis expands global footprint with acquisition of production facility in Southeast Asia

Novonesis expands global footprint with acquisition of production facility in Southeast Asia

Novonesis expands global footprint with acquisition of production facility in Southeast Asia

 

Investment of around USD 50 million strengthens fermentation capabilities and supports the company’s long-term growth ambitions.

COPENHAGEN, Denmark – April 8, 2026. Novonesis has signed an agreement with Meihua to acquire a production facility in Rayong, Thailand for around USD 50 million, increasing the company’s footprint in Southeast Asia and strengthening its ability to serve customers worldwide.



Expanding in Asia is core to Novonesis' GROW strategy towards 2030. Emerging markets already account for one third of the company's sales and are expected to grow faster than developed markets. By investing in geographically well-positioned facilities, the company strengthens its capabilities to supply both local and global markets with its unique global multipurpose production setup.

Novonesis is acquiring a facility with advanced fermentation capabilities that can be further expanded to support the company’s growth journey, including the production of HMO (human milk oligosaccharides). Novonesis plans to invest further in the facility over the coming years to maximize its potential and establish a strong operational setup. The company expects the site to be commercially operational in 2027.

Anders Lund, Chief Operating Officer: 

“Strengthening our production footprint in Southeast Asia is an important step for Novonesis. A key part of our GROW strategy is to continue to strengthen our resilient and responsive supply network to support our long-term growth ambitions. By expanding our world-class production capabilities, we can move closer to customers in a fast-growing region and deliver even greater value to them."

 

Novonesis investing in capacity and resilience across markets

The Rayong acquisition is one of several investments Novonesis has made in recent years to strengthen its resilience and global production setup – enabling the company to serve local customers more effectively and drive growth. Facilities in Franklinton, North Carolina, Taicang, China, Araucaria, Brazil, and West Allis, Wisconsin, have been expanded as part of this effort.

Over the current strategy period towards 2030, Novonesis expects to increase its growth-focused capital expenditure and cater for the increasing demand for biosolutions among customers and consumers.

Get in touch



Line Emilie Fedders

Senior Media Relations Manager



Tobias Bjorklund

Head of Investor Relations











EN
08/04/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE

Novonesis expands global footprint with acquisition of production faci...

Novonesis expands global footprint with acquisition of production facility in Southeast Asia Novonesis expands global footprint with acquisition of production facility in Southeast Asia Investment of around USD 50 million strengthens fermentation capabilities and supports the company’s long-term growth ambitions. COPENHAGEN, Denmark – April 8, 2026. Novonesis has signed an agreement with Meihua to acquire a production facility in Rayong, Thailand for around USD 50 million, increasing the company’s footprint in Southeast Asia and strengthening its ability to serve customers worldwide.Expand...

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full announcement in PDF. Attachment

 PRESS RELEASE

Resolutions from the Annual General Meeting 2026

Resolutions from the Annual General Meeting 2026 Today, the Annual General Meeting of Novonesis (Novozymes A/S) was conducted. The following resolutions were made: Approval of the audited Annual Report for 2025Approval of distribution of profit with payment of an ordinary dividend of DKK 4.25 (corresponding to approximately EUR 0.57) per A and B share. In addition to this year-end dividend, an interim dividend of DKK 2.25 (corresponding to approximately EUR 0.3) was disbursed on August 27, 2025Approval of the Remuneration Report for 2025 (advisory vote)Approval of the remuneration of membe...

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full announcement in PDF. Attachment

 PRESS RELEASE

Novonesis issues EUR 1.7 billion in bonds to refinance bridge facility

Novonesis issues EUR 1.7 billion in bonds to refinance bridge facility COPENHAGEN, Denmark – March 16, 2026. Novonesis has completed a EUR 1.7 billion bond issuance, with significant interest from a broad group of investors. The transaction was primarily undertaken to refinance the bridge facility related to Novonesis’ purchase of the dsm firmenich’s part in the Feed Enzyme Alliance, closed in June 2025. The acquisition gives Novonesis full control of the alliance’s sales and distribution, strengthening the company’s position across the animal biosolutions value chain. Rainer Lehmann, CFO...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch